A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety and effectiveness of APTO-253 for the
treatment of patients with the condition of acute myelogenous leukemia (AML) or
myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no
longer effective, or can no longer be administered safely or poses a risk for your general
well being.